Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing transformative medicines for serious diseases. The company is best known for its leadership in cystic fibrosis, where it markets a portfolio of CFTR modulator therapies such as Trikafta/Kaftrio, Symdeko/Symkevi, Orkambi, Kalydeco and Alyftrek that address underlying genetic defects in eligible patients across multiple age groups. Beyond cystic fibrosis, Vertex today provides and develops treatments for sickle cell disease, transfusion-dependent beta thalassemia, and moderate-to-severe acute pain, as well as investigational therapies for APOL1-mediated kidney disease and other severe conditions. Headquartered in Boston, Massachusetts and founded in 1989, Vertex operates across the United States, Europe, and internationally, serving specialized markets through a combination of proprietary drug development, advanced research collaborations, and global commercialization capabilities. Its portfolio positions the company as a key player in specialty care within the broader healthcare and biotechnology sectors.